GET DAILY SIGNALSConcentra (CON) Reports Strong Q3 Earnings with +8.6% Revenue Growth and Guidance Raise
Key Takeaways
- Revenue reached $622.1 million, up 8.6% year over year and above the consensus estimate of about $605.5 million.
- Adjusted earnings per share (EPS) came in at $0.52, beating the consensus estimate of $0.44.
- Net income attributable to the company rose 36.5% to $65.9 million, while adjusted EBITDA climbed 17.9% to $140.2 million.
- Patient visits grew 4.9%, revenue per visit rose 3.3%, and the company expanded to 639 occupational health centers.
- Concentra raised its full-year 2026 guidance and announced a new $250 million share repurchase program alongside a quarterly dividend.
- The quarter also marked a leadership transition, with Matt DiCanio stepping into the chief executive officer role effective November 1, 2026.
Why These Results Matter
Concentra Group Holdings is the largest provider of occupational health services in the United States, operating a network of centers that treat workplace injuries and manage employer health programs. Its results serve as a real-time read on labor-market activity, since patient volume tracks the number of workers across manufacturing, transportation, and other industries. The third-quarter report was also notable for a shift in leadership, giving investors a first look at how the company is positioning for its next growth phase. With a history of beating estimates and a guidance raise accompanying these results, the report offers important signals about demand, pricing power, and the sustainability of margin expansion. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Breaking Down the Numbers
For the third quarter ended September 30, 2026, CON reported revenue of $622.1 million, an 8.6% increase from $572.8 million in the prior-year period and above the analyst consensus of roughly $605.5 million. Adjusted EPS came in at $0.52, exceeding the consensus estimate of $0.44 and rising 36.8% year over year.
Net income attributable to the company grew 36.5% to $65.9 million, while adjusted EBITDA increased 17.9% to $140.2 million. Operating momentum was broad-based: patient visits rose 4.9% to about 3.7 million, revenue per visit increased 3.3% to $152.14, and the center count expanded to 639 locations from 628 a year earlier.
Management also raised its full-year 2026 outlook, now projecting revenue of $2.36 billion to $2.38 billion and adjusted EBITDA of $505 million to $510 million. The board declared a $0.0625 per-share dividend and authorized a new $250 million buyback program.
Market Reaction and Investor Sentiment
CON has developed a track record of exceeding expectations, and shares rallied sharply following its prior-quarter beat. The combination of a revenue and earnings beat, expanded margins, and raised guidance in this report is consistent with the themes the market has rewarded in recent quarters. That said, investors were also weighing a year-over-year decline in quarterly free cash flow and a period of leadership transition. With results released after the market close on November 5, 2026, the market's initial interpretation focused on the durability of patient-volume growth, pricing strength, and the credibility of the raised full-year outlook.
Forward Outlook and Key Factors to Monitor
The raised guidance signals management's confidence that demand trends remain intact. Investors will now watch whether patient-volume growth and the roughly 3% rate of per-visit pricing growth can be sustained into 2027, especially as employment conditions across key industries evolve.
Leadership transition is another area of focus. With Matt DiCanio now serving as CEO and Keith Newton moving to executive chairman, the market will assess whether the company's expansion strategy, including new center openings and targeted acquisitions, continues without disruption. Concentra opened three new centers and completed a four-center acquisition during the quarter.
Capital allocation will also matter. The new $250 million buyback authorization, the declared dividend, debt repayment, and an S&P credit-rating upgrade all point to a stronger balance sheet, reflected in a net leverage ratio of 2.90x. Finally, investors should monitor margin and free cash flow trends, which will indicate how efficiently the company converts higher patient volumes into cash as it scales its network. From what I see, these elements together paint a constructive picture for the business.
Exploring AI Tools in My Analysis
In my ongoing research on names like CON, I find it helpful to run additional screens for comparable companies and technical setups. One resource I turn to regularly is Tickeron’s AI Screener, which lets users filter stocks and ETFs by patterns, fundamentals, and AI-driven signals to surface ideas more efficiently.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CON in -0.57% downward trend, sliding for three consecutive days on November 03, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where CON declined for three days, in 83 of 131 cases, the price declined further within the following month. The odds of a continued downward trend are 63%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
CON broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 02, 2026. You may want to consider a long position or call options on CON as a result. In 29 of 45 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 64%.
The Moving Average Convergence Divergence (MACD) for CON just turned positive on October 05, 2026. Looking at past instances where CON's MACD turned positive, the stock continued to rise in 14 of 18 cases over the following month. The odds of a continued upward trend are 78%.
Following a +3.12% 3-day Advance, the price is estimated to grow further. Considering data from situations where CON advanced for three days, in 96 of 131 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
The Aroon Indicator entered an Uptrend today. In 52 of 85 cases where CON Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 61%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 21 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. CON’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.643) is normal, around the industry mean (204.059). P/E Ratio (28.103) is within average values for comparable stocks, (18.581). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.498). Dividend Yield (0.006) settles around the average of (0.091) among similar stocks. P/S Ratio (2.035) is also within normal values, averaging (2.688).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry HospitalNursingManagement
Advertisement